Bibliographie :
(1) ALK in Lung Cancer: ESMO Biomarker Factsheet. Disponible à partir de l’URL : https://oncologypro.esmo.org/Education-Library/Factsheets-on-Biomarkers/ALK-in-Lung-Cancer. Last update: 02 August 2015
(2) Les traitements des cancers. Disponible à partir de l’URL : https://www.e-cancer.fr/Professionnels-de-sante/Les-traitements. Date de dernière mise à jour : 24/05/2018
(3) Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer D.R. Camidge, NEJM September 25, 2018
(4) Guides pour les patients ESMO. Disponible à partir de l’URL : https://www.esmo.org/content/download/7250/143186/file/FR-Cancer-du-Poumon-non-a-Petites-Cellules-Guide-pour-les-Patients.pdf
(5) Dong-Wan K et al. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. Journal of Clinical Oncology. J Clin Oncol 35:2490-2498.
(6) Shaw AT et al. Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer. N Engl J Med. 2014;370(13):1189-1197
(7) Justin f. Gainor, et al. Molecular mechanism of resistance to first and Second-Generation ALK inhibitor ALK-rearranged Lung Cancer. ACR. 2016;6(10):1118-1133
(8) Source : http://clincancerres.aacrjournals.org/content/18/10/2740.figures-only